Core Insights - Major U.S. stock market indices reached record highs as investors anticipate the Federal Reserve's policy decision, with the S&P 500 climbing 0.23% to 6,890.89, briefly surpassing the 6,900 mark for the first time [1][10] - The Federal Reserve is expected to announce a quarter-point rate cut, with potential additional cuts in the future, despite a slight increase in September inflation [2] - Value investing is gaining traction in the current economic uncertainty, focusing on stocks priced below their intrinsic value [3][10] Market Overview - The Dow, S&P 500, and Nasdaq all achieved new highs, indicating strong investor sentiment [1] - Analysts believe the Fed will prioritize supporting a softening labor market over controlling inflation, although missing economic data due to the government shutdown may complicate policy signals [2] Investment Strategy - Value investing emphasizes purchasing undervalued stocks, which can provide opportunities for profit as markets often misprice stocks [3] - Companies with solid fundamentals and reasonable valuations are highlighted as potential investment opportunities [4] Earnings Yield Metric - Earnings yield is a key metric for value investors, calculated as (Annual Earnings per Share/Market Price) x 100, and serves as a comparison tool against bond returns [5][6] - A high earnings yield may indicate that a stock is undervalued, while a low yield could suggest overvaluation [5] Stock Screening Criteria - The primary screening criterion is an Earnings Yield greater than 10%, supplemented by estimated EPS growth and average daily volume [7][8] - Additional filters include a current price of at least $5 and a Zacks Rank of 1 (Strong Buy) or 2 (Buy) for stock selection [9] Selected Value Stocks - Aura Minerals Inc. (AUGO) is focused on gold and base metal projects, with projected earnings growth of 120.3% and 165.6% for 2025 and 2026, respectively [11] - Commercial Metals Company (CMC) anticipates sales and earnings growth of 5% and 73% for fiscal 2026 [12] - Par Pacific Holdings (PARR) projects significant earnings growth of 951% and 24% for 2025 and 2026 [13] - CorMedix Inc. (CRMD) expects earnings growth of 717% and 34% for 2025 and 2026 [14]

Janux Therapeutics, Inc. ( JANX ) presents a rather interesting scenario for speculators. With an early-stage pipeline that has shown a few signals of promise, the primary driver of market sentiment has been aI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of inve ...

Core Viewpoint - The article emphasizes the importance of identifying and maintaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for sustaining momentum in stocks [1]. Group 1: Recent Price Strength Screen - The "Recent Price Strength" screen is a unique short-term trading strategy that helps identify stocks with strong fundamentals capable of maintaining an uptrend [2]. - Stocks that pass this screen are typically trading in the upper portion of their 52-week high-low range, indicating bullish sentiment [2]. Group 2: MDxHealth SA (MDXH) Analysis - MDxHealth SA (MDXH) has shown a significant price increase of 100.8% over the past 12 weeks, indicating strong investor interest [3]. - A recent price increase of 7.5% over the last four weeks suggests that the upward trend is still intact for MDXH [4]. - MDXH is currently trading at 91.7% of its 52-week high-low range, suggesting it may be on the verge of a breakout [4]. Group 3: Fundamental Strength - MDXH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The Zacks Rank system has a strong track record, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [6]. - The Average Broker Recommendation for MDXH is 1 (Strong Buy), indicating high optimism from the brokerage community regarding its near-term price performance [6]. Group 4: Additional Investment Opportunities - Besides MDXH, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [7]. - The article encourages exploring over 45 Zacks Premium Screens tailored to different investing styles for potential stock picks [7].

Data from the dose optimization trial expected soonProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company pioneering innovative therapies for viral diseases, is pleased to announce the successful completion of its second randomized double-blind, placebo-controlled clinical trial for its leading broad-spectrum antiviral drug candidate, ProLectin-M. ...

We recently published 10 Stocks Soaring by Double Digits; Uranium Stocks Leading. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the top-performing stocks on Tuesday. Arcutis jumped to a fresh record high on Tuesday, as investors cheered a stellar earnings performance in the third quarter of the year, having more than doubled its revenues to reach profitability during the period. In intra-day trading, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) jumped to its highest 52-week price of $25.75 before tr ...

Financial Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $14.3 million, a decrease from $14.6 million in Q3 2024, primarily due to reduced employee compensation costs and decreased costs associated with a discontinued program [10] - General administrative expenses decreased to $7.6 million in Q3 2025 from $8.4 million in Q3 2024, mainly due to lower professional services costs [10] - The net loss for Q3 2025 was $19.6 million, compared to a net loss of $21.7 million in Q3 2024 [11] - Cash, cash equivalents, and marketable securities at the end of Q3 2025 totaled $200.6 million, down from $241 million at the end of 2024, primarily due to cash used for operating activities [11] - The company expects its existing cash resources to fund operations into 2028, allowing for substantial progress in clinical development [11] Business Line Data and Key Metrics Changes - The lead program, FTX-6058, for sickle cell disease showed promising results, including a dose-dependent increase in fetal hemoglobin and a reduction in vaso-occlusive crises [5][8] - Enrollment in the 20-milligram dose cohort was completed with 12 evaluable patients, and data will be presented at the upcoming ASH conference [6][7] - The company is also advancing programs for bone marrow failure syndromes and plans to submit an IND for these conditions in Q4 2025 [9] Market Data and Key Metrics Changes - Approximately 100,000 people in the U.S. and 7.7 million worldwide suffer from sickle cell disease, indicating a significant market need for effective treatments [4] - The company estimates that about 20% of the U.S. sickle cell disease population meets the inclusion-exclusion criteria for the Phase 1B Pioneer trial [35] Company Strategy and Development Direction - The company aims to position FTX-6058 as a best-in-class once-daily oral therapy for sickle cell disease, with plans for an open-label extension trial to evaluate long-term safety and efficacy [6][8] - The strategy includes engaging with the FDA for an end-of-Phase 1 meeting in Q1 2026 to discuss the next stages of clinical development [8] - The company is focused on expediting the drug's market entry to address the unmet needs of sickle cell disease patients globally [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the encouraging results from the 12-milligram cohort and the upcoming data readout at the ASH conference [12][13] - The management team highlighted the importance of generating additional safety data through the open-label extension study, which is expected to inform future discussions with the FDA [24][75] Other Important Information - The company has seen a high adherence rate of over 90% among patients in the study, indicating strong patient engagement with the treatment regimen [7] - The management team emphasized the need for a comprehensive approach to evaluating the drug's efficacy, considering multiple parameters such as fetal hemoglobin levels and reduction in vaso-occlusive crises [52] Q&A Session Summary Question: How does the company define a win in the context of the trial results? - Management believes they have already achieved a win with the 12-milligram cohort, showing robust increases in fetal hemoglobin and a favorable safety profile [16] Question: What are the expectations for the 20 mg dose cohort? - Management anticipates that the 20 mg cohort will outperform the 12 mg cohort based on previous healthy volunteer data [18] Question: What is the addressable market following the withdrawal of a competitor's product? - The company estimates that about 20% of the 100,000 U.S. patients with sickle cell disease currently meet the trial criteria, with plans to discuss potential market expansion with the FDA [35] Question: What metrics will be important for defining the activity of FTX-6058? - Management indicated that the totality of data, including fetal hemoglobin levels, pan-cellularity, and reduction in markers of hemolysis, will be crucial for evaluating the drug's efficacy [52] Question: What is the timeline for the final Pioneer data set? - The full data set is expected to be available in the first quarter of the following year [56]

Core Insights - 10x Genomics has launched a next-generation high-performance Flex assay that features automation-compatible plate-based multiplexing, enabling cost-effective and scalable single-cell analysis for a variety of research applications [1][2][3] Group 1: Product Features - The new Flex assay allows researchers to profile up to 384 samples and 100 million cells per week using a 96-well plate format, integrating seamlessly with automated cell partitioning for reliable results [2] - Built on proven Flex chemistry, the assay offers exceptional sensitivity and sequencing efficiency, supporting modular usage and reducing reagent waste, thus delivering more data at a lower cost [2][3] - The assay enables the profiling of millions of cells at a fraction of the cost compared to traditional methods, significantly enhancing the ability to explore functional immune responses [4] Group 2: Market Impact - The advancements in scalability and ease of use are expected to unlock more research opportunities, allowing for more samples, conditions, and insights at reduced costs [3] - The new Flex assay is positioned as a transformative tool for large-scale foundational and translational studies, as well as routine single-cell applications [3] - Early access customers have already begun utilizing the new Flex assay across various discovery and translational research programs, indicating strong market interest [3][4] Group 3: Company Overview - 10x Genomics is a life science technology company focused on products that accelerate biological research and advance human health, with solutions that include instruments, consumables, and software for single-cell and spatial biology [5] - The company's products have contributed to breakthroughs in various fields, including oncology, immunology, and neuroscience, enhancing the understanding of health and disease [5]

Core Points - Creative Medical Technology Holdings, Inc. has entered into agreements for the immediate exercise of existing warrants to purchase up to 1,116,136 shares of common stock at an exercise price of $3.75 per share, expected to generate approximately $4.2 million in gross proceeds [1][4] - The company will issue new unregistered warrants for an aggregate of up to 2,790,340 shares at the same exercise price, with potential adjustments based on the lowest VWAP during a specified period [3] - The transaction is anticipated to close on or about October 29, 2025, subject to customary closing conditions, with proceeds intended for working capital and general corporate purposes [4] Financial Advisory - Roth Capital Partners is acting as the financial advisor for this transaction [2] Regulatory Compliance - The new warrants were offered in a private placement and have not been registered under the Securities Act of 1933, with the company agreeing to file a registration statement with the SEC for the resale of shares [5]

SHELTON, CONNECTICUT / ACCESS Newswire / October 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share major progress in the company's antiviral research in a video interview. ...

Core Insights - PDS Biotechnology Corporation is seeking an expedited approval pathway from the FDA for its immunotherapy PDS0101 targeting HPV16-positive head and neck cancer, projected to be the most prevalent type of head and neck cancer in the US by the mid-2030s [1][2] Company Overview - PDS Biotechnology is a late-stage immunotherapy company focused on innovative cancer treatments, particularly through its lead program PDS0101, which is being developed in combination with standard immune checkpoint inhibitors [4] Clinical Trials - The VERSATILE-002 trial has shown promising results, reporting a median overall survival (mOS) of 39.3 months and a median progression-free survival (PFS) of 6.3 months, leading to a proposed amendment in the ongoing VERSATILE-003 trial to include PFS as an earlier primary endpoint [1][2][3] - The VERSATILE-002 trial is an open-label, multi-center Phase 2 study evaluating the safety and efficacy of PDS0101 in combination with pembrolizumab for patients with unresectable, recurrent, or metastatic HPV16-positive head and neck cancer [3] Regulatory Strategy - The company plans to meet with the FDA to discuss changes to the current trial protocol, aiming to shorten the trial duration by making PFS an earlier primary endpoint, which could facilitate an accelerated approval submission [1][2]